Mesalazine for the Treatment of Diarrhoea-predominant Irritable Bowel Syndrome (IBS-D)
Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
The purpose of the trial is to define the clinical benefit and possible mediators of the
benefit of mesalazine in Irritable Bowel Syndrome (IBS) with diarrhoea.
The investigators will therefore evaluate symptoms (primarily bowel frequency) and markers
reflecting mast cell activation and small bowel tone.
Phase:
Phase 4
Details
Lead Sponsor:
University of Nottingham
Collaborator:
National Institute for Health Research, United Kingdom